The inhibitory effect of statins on urinary 11-dehydrothromboxane levels

International Angiology

Volumn 29, Issue 3, 2010, Pages 255-259

  Alusik S ^a,b   Paluch, Z ^a   Lejskova M ^a   Adamek T ^a  

^a FAKULTNÍ THOMAYEROVA NEMOCNICE   (Czech Republic)

^b IPVZ   (Czech Republic)

Author keywords

11 dehydrothromboxane B2; Aspirin; C reactive protein; Statins

Indexed keywords

11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; ATORVASTATIN; C REACTIVE PROTEIN; CHOLESTEROL; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; URINE LEVEL;

AGED; ASPIRIN; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PLATELETS; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CZECH REPUBLIC; DOWN-REGULATION; FATTY ACIDS, MONOUNSATURATED; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PYRROLES; SIMVASTATIN; THROMBOXANE B2; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 77956086477     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Pradelles P, Grassi J, Macloud J. Enzyme immunoassay of eicosanoids using acetylcholinesterase as label: An alternative to radioimmunoassay. Clin Chem 1985;57:1170-3.
2. Perneby C, Granstrom E, Beck O. Optimization of an enzyme immunoassay for 11-dehydro-thromboxane B(2) in urine: comparison with GC-MS. Thromb Res 1999;96:427-36.
3. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-5.
4. Eikelboom JW, Hankey GJ, Thom J, Bhatt DL, Steg G, Montalescot G et al. Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid. Determinants and effect on cardiovascular risk. Circulation 2008;118:1705-12.
5. Schror K, Lobel P, Steinhagen-Thiessen E. Simvastatin reduces platelet thromboxane formation and restores normal platelet sensitivity against prostacycline in type IIa hypercholesterolemia. Eikosanoids 1989;2:39-45.
6. Schror K. Platelet reactivity and arachidonic acid metabolism in type II hyperlipoproteinemia and its modification by cholesterol lowering agents. Eikosanoids 1999;3:67-73.
7. Notarbartolo A, Davi G, Averna M, Barbagallo CM, Ganci A, Giammarresi C et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995;15:247-51.
8. Marwali MR, Hu CP, Mohandas B, Dandapat A, Deonikar P, Chen J et al. Modulation of ADP-induced platelet activation by aspirin and pravastatin: Role of lectin-like oxidized low-density lipoprotein receptor-1, nitric oxide, oxidative stress, and inside-out integrin signaling. J Pharmacol Exp Ther 2007;322:1324-32.
9. Haramaki N, Ikeda H, Takenaka K, Katoh A, Sugano R, Yamagishi S et al. Fluvastatin alters platelet aggregability in patients with hypercholesterolemia. Thromb Vasc Biol 2007;27:1471-7.
10. Piorkowski M, Fischer S, Stellbaum C, Jaster M, Martus P, Morguet AJ et al. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone. Is sufficient cholesterol-lowering enough to inhibit platelets? J Am Coll Cardiol 2007;49:1035-42.
11. Tirnaksiz E, Pamukcu B, Oflaz H, Nisanci Y. Effect of high dose of statin therapy on platelet function: statins reduce aspirin resistant platelet aggregation in patients with coronary heart disease. J Thromb Thrombolysis 2007;Oct 5 (Epub ahead of print).
12. Robinson JG. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effect, and cardiovascular risk. Am J Cardiol 2008;101:1009-15.
13. Maree O, Fitzgerald DJ. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation 2007;115:2196-207.
14. Ferguson AD, Dokainish H, Lakkis N. Aspirin and clopidogrel response variability. Tex Heart Inst J 2008;35:313-20.
15. McGlasson DL, Chen M, Fritsma GA, Knight ZA, Dobbs M. Urinary 11-dehydrothromboxane B2 levels in healthy individuals following a single dose response to two concentrations of aspirin. J Clin Ligand Assay 2005;28:147-50.
16. Cerletti C, Elba GD, Manarini S, Pecce R, Castelnuovo AD, Scorpiglione N et al. Pharmacokinetic and pharmacodynamic differences between two low dosages of aspirin may affect therapeutic outcomes. Clin Pharmacokinet 2003;42:1059-70.
17. Albert MA, Danielson E, Rifai N, Ridker PM for the PRINCE Investigators. Effect of statin therapy on C-reactive protein levels. The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial cohort study. JAMA 2001;286:64-70.
18. Balk EM, Lau J, Coudas L, Jordan HS, Kupelnick B, Kim LU et al. Effect of statins on nonlipid serum markers associated with cardiovascular disease. Ann Intern Med 2003;139:670-82.
19. Habib A, Shamseeddeen I, Nasrallah MS, Antoun TA, Nemer G, Bertoglio J et al. Modulation of COX-2 expression by statins in human monocytic cells. FASEB J 2007;21:1665-74.
20. Fisher M, Cushman M, Knappertz V, Howard G. An assessment of the joint associations of aspirin and statin use with C-reactive protein concentration. Am Heart J 2008;156:106-11.